Topical Bimatoprost in the Treatment of Migraine

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Migraine Disorders, Headache Disorders

In brief

The study is to assess the effectiveness of topically applied bimatoprost in reducing migraine headache frequency, severity, and duration. It will also assess the effect of topical bimatoprost on quality of life.

Key facts

Study ID

NCT03419715

Run by

Manistee Partners

People needed

70

Starts

2018-01-05

Expected to finish

2019-06-30

Last updated by the study team

2019-04-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of migraines based on International Classification of Headache Disorders (ICHD) II criteria and experiencing headaches for 4 or more days per month.

You may not qualify if…

• Significant liver or renal dysfunction,
• On treatment for inflammatory bowel disease, medication over-use for headaches according to the ICHD II criteria,
• Use of antipsychotics in the past month,
• Recent (in the past six months) history of alcohol or drug abuse,
• Allergy to bimatoprost and its compounds,
• Severe comorbid psychiatric illness,
• Severe infection,
• Malignancy,
• Severe cardiovascular disease,
• Neurodegenerative disorders,
• Pregnancy and lactation, and
• Sexually active women of child bearing age who do not use any method of contraception.

Where it is running

• CTI Clinical Trial and Consulting Services — Cincinnati, Ohio, United States
• Omega Medical Research — Warwick, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.